Volixibat potassium manufacturers
- Angstrom6
-
- $49.00
-
2026-07-27
- CAS:220334-14-5
- Purity: 99.97%
- Supply Ability: 10g
|
| | Volixibat potassium Basic information |
| Product Name: | Volixibat potassium | | Synonyms: | Volixibat potassium;Angstrom6/A6 Peptide;A-6 peptide;L-α-Glutamine, N2-acetyl-L-lysyl-L-prolyl-L-seryl-L-seryl-L-prolyl-L-prolyl-L-α-glutamyl-;P1161 Angstrom6;A-6|||A 6 peptide|||A6|||A 6|||A6 peptide|||A-6 peptide;(S)-N-((S)-1-Amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-2-((S)-2-((S)-2-((S)-2-((S)-2-amino-3-phenylpropanamido)-3-hydroxypropanamido)-4-methylpentanamido)-4-methylpentanamido)-5-guanidinopentanamide;Volixibat potassium/A 6 (Peptide) | | CAS: | 220334-14-5 | | MF: | C39H62N10O15 | | MW: | 910.97 | | EINECS: | | | Product Categories: | | | Mol File: | 220334-14-5.mol |  |
| | Volixibat potassium Chemical Properties |
| Boiling point | 1469.3±65.0 °C(Predicted) | | density | 1.409±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | pka | 4.44±0.10(Predicted) | | form | Solid | | color | White to off-white | | Sequence | Ac-Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu-NH2 |
| | Volixibat potassium Usage And Synthesis |
| Uses | Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling[1][2]. | | in vivo | Angstrom6 (100 mg/kg; s.c. twice daily) reduces the number of lung foci generated by the i.v. injection of B16-F10 melanoma cells by 50%[3]. | Animal Model: | C57Bl/6 mice (bearing B16-F10 cells)[3] | | Dosage: | 100 mg/kg | | Administration: | S.c.; twice a day for 11 days | | Result: | Reduced the number of lung nodules and reduced the number of lung metastases to 50% of control.
|
| | References | [1] Ghamande SA, et al. A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer. Gynecol Oncol. 2008;111(1):89-94. DOI:10.1016/j.ygyno.2008.06.028
[2] Finlayson M. Modulation of CD44 Activity by A6-Peptide. Front Immunol. 2015;6:135. Published 2015 Mar 30. DOI:10.3389/fimmu.2015.00135
[3] Piotrowicz RS, et al. A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells. Mol Cancer Ther. 2011;10(11):2072-2082. DOI:10.1158/1535-7163.MCT-11-0351 |
| | Volixibat potassium Preparation Products And Raw materials |
|